Jump to content

Tadocizumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Magic links bot (talk | contribs) at 04:27, 2 July 2017 (Replace magic links with templates per local RfC and MediaWiki RfC). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tadocizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetIntegrin αIIbβ3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC2107H3252N562O673S12
Molar mass47.6 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.[2]

The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]

References

  1. ^ a b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
  2. ^ Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tadocizumab&oldid=788567160"